Natco Pharma Faces Continued Decline Amid Broader Sector Weakness and Underperformance

Natco Pharma has experienced a significant decline of 5.19% on April 4, 2025, closing at Rs 793.7, which is just 4.86% above its 52-week low of Rs 757.75. The stock's performance today has underperformed the broader pharmaceuticals and drugs sector, which also fell by 5.2%.
In terms of moving averages, Natco Pharma is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Over the past day, the stock's performance of -5.03% contrasts sharply with the Sensex's decline of only 1.09%.

Looking at longer-term performance metrics, Natco Pharma has faced a challenging year, with a year-to-date decline of 42.73% compared to the Sensex's drop of 3.42%. Over the past three months, the stock has plummeted by 41.88%, while the Sensex has only decreased by 4.75%. In the last five years, Natco Pharma has shown a gain of 53.98%, but this is significantly lower than the Sensex's impressive 173.51% increase during the same period.